Overview

Lifecore Biomedical is a fully integrated Contract Development and Manufacturing Organization (CDMO) offering expertise in specialty formulation, aseptic filling, and final packaging of both complex medical devices and injectable pharmaceuticals. We currently manufacture FDA-approved commercial products at our three cGMP facilities and have received numerous certifications from regulators in Europe, Japan, and Brazil as well as the International Organization for Standardization (ISO).

Lifecore has also been a leading manufacturer of pharmaceutical-grade, non-animal-sourced hyaluronic acid (HA) since 1981 when we developed our proprietary, fermentation-based HA process. Since then, we have become the preferred viscoelastic supplier to ophthalmic market leaders and our products have been used in the treatment of more than 100 million patients worldwide.

For decades, Lifecore’s commitment to customers has enabled our success and allowed us to expand our infrastructure, increasing capacity to help support growing demands from the global pharmaceutical market.

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

14 Nov '22
Common stock expected to begin trading tomorrow under new Nasdaq ticker symbol “LFCR” Lifecore global headquarters relocated to Chaska, MN Launches new investor relations website: ir.lifecore.com CHASKA, Minn., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc.
06 Oct '22
Lifecore segment revenues increased 8.0% to $23.7 million in fiscal 2023 first quarter versus the prior year period Lifecore segment EBITDA increased 8.1% to $2.5 million in fiscal 2023 first quarter versus the prior year period Reiterates fiscal 2023 full year guidance for Lifecore Corporate

Recent Events